Sanofi Receives Marketing Nod for Dupixent in India

Sanofi Healthcare India Pvt. Ltd. announced earlier this week that Dupixent (dupilumab) has received marketing approval. According to a statement, this is the first biologic medication for adults with moderate-to-severe atopic dermatitis who do not have adequate control of their condition with topical prescription treatments or when those treatments are not recommended. Atopic dermatitis, a type of eczema, causes a persistent skin rash and is classified as a chronic type 2 inflammatory condition. Moderate-to-severe atopic dermatitis symptoms typically include extensive rash coverage across the body, as well as intense and persistent itching.

Affected individuals may also experience skin dryness, cracking, redness, crusting, and oozing. Dupixent will soon be available in India as a potential treatment for moderate to severe atopic dermatitis in adults. Sanofi and Regeneron collaborated on the development of dupilumab as part of a global partnership agreement. Dupixent can be used alone or in combination with topical therapy. "The approval of Dupixent for marketing in India is a significant milestone for us, as we now have the opportunity to offer our first-in-class and best-in-class therapy to people living with atopic dermatitis in India."

Approved in the U.S., the European Union, Japan and more than 60 countries for one or more indications other than atopic dermatitis, Dupixent® is the first and only biologic medicine in India that has shown significantly improved disease signs, symptoms, and quality of life measures, for this particularly difficult-to-treat skin condition” said Anil Raina, General Manager, Sanofi Specialty Care (India).